Regenxbio reports Q4 EPS ($1.01), consensus ($1.08)

Reports Q4 revenue $21.2M, consensus $23.7M. Expects its balance in cash, cash equivalents and marketable securities of $244.9M as of December 31, 2024 and the $110.0M upfront payment to be received under the Nippon Shinyaku collaboration to fund its operations into the second half of 2026. “Regenxbio (RGNX) is on the cusp of delivering potential first- or best-in-class gene therapies to market. In 2025, we have already submitted our first BLA and will accelerate late-stage development and advance commercial preparations for multiple potential product launches,” said CEO Curran Simpson. “RGX-202 is progressing rapidly through pivotal study, continues to demonstrate a differentiated profile, and remains on track to be the next gene therapy in Duchenne. Our partnership with AbbVie continues to advance multiple large, global commercial opportunities. Now partnered with Nippon Shinyaku, RGX-121 is poised to bring another meaningful revenue stream to Regenxbio if approved in the coming months. We remain focused on bringing multiple potentially transformative new medicines to patients.”